Cyproheptadine: The Anti-Serotonin Research Tool (Complete Guide)

Cyproheptadine is a first-generation H1 antihistamine with a receptor-binding profile that sets it apart from every other antihistamine on the market: alongside its H1 antagonism, it is a potent antagonist at the 5-HT2A and 5-HT2C serotonin receptor subtypes - the two 5-HT receptor subtypes most directly implicated in peripheral vasoconstriction, metabolic suppression, and cortisol-amplifying serotonin signaling. This dual mechanism - H1 antihistamine plus 5-HT2 serotonin antagonist - is the pharmacological property that has made cyproheptadine the bioenergetic-research community's preferred pharmacological anti-serotonin tool for over two decades.

In the mainstream clinical world, cyproheptadine is known primarily as an appetite stimulant, a pediatric antihistamine, and a treatment for serotonin syndrome - the potentially life-threatening excess-serotonin toxidrome that can develop from serotonergic drug combinations. In the bioenergetic-research community, it occupies a different role: the cleanest pharmacological lever available for directly suppressing serotonin signaling at the 5-HT2 receptor level, without the mechanism complexity of SSRIs, the dopamine antagonism of atypical antipsychotics, or the non-selective receptor profile that limits other anti-serotonin compounds. Cyproheptadine's simplicity and specificity are precisely what the bioenergetic framework requires.

This guide covers cyproheptadine's molecular profile, its dual mechanism, the Ray Peat anti-serotonin context that made it central to the bioenergetic protocol stack, its documented effects on appetite, sleep, and anxiety, and the canonical bioenergetic pairing of cyproheptadine with slow-release T3.

Research framing. This guide reviews cyproheptadine from a research-context standpoint. All compounds discussed are sold strictly for laboratory research and not for human consumption. See our /faq#legality page for full terms.

What Is Cyproheptadine?

Cyproheptadine hydrochloride is a piperidine-class tricyclic compound with the molecular formula C21H21N, a molecular weight of 287.4 g/mol, and a structural profile that places it in the same tricyclic chemical family as pizotifen and pimethixene. The tricyclic core is a dibenzocycloheptadiene ring system - the same scaffold that gives many first-generation antihistamines their multi-receptor activity, because the extended aromatic structure allows binding to multiple aminergic receptor classes simultaneously. This structural promiscuity is not a pharmacological liability in cyproheptadine's case; it is the source of the dual-mechanism action that defines its research utility.

Cyproheptadine was first synthesized in the late 1950s and received FDA approval in 1961, initially indicated for the management of allergic conditions (hay fever, urticaria, angioedema) and as an appetite stimulant in underweight adults and children. The appetite-stimulating indication was documented from the earliest clinical trials and has remained one of the best-characterized effects in the cyproheptadine literature - a direct consequence of 5-HT2C antagonism, as discussed in the mechanism section below. In subsequent decades, cyproheptadine accumulated a series of off-label applications that reflect its 5-HT2 receptor activity: prophylaxis for serotonin-syndrome-prone drug combinations, migraine prophylaxis (via 5-HT2-mediated vasoconstriction inhibition), and treatment of the acute serotonin syndrome where rapid 5-HT2 receptor blockade is required.

Unlike second-generation antihistamines (cetirizine, loratadine, fexofenadine), which were engineered specifically for peripheral H1 activity with minimal CNS penetration, cyproheptadine crosses the blood-brain barrier effectively. This CNS penetrance is responsible for both its sedative properties (H1 blockade in the CNS is the classic first-generation antihistamine sedation mechanism) and its central anti-serotonin actions - including the sleep-depth effects and anxiolytic actions that the bioenergetic research community uses alongside the peripheral anti-serotonin function.

The Ray Peat Context: Why Anti-Serotonin Matters

The bioenergetic framework developed by Ray Peat and the research community he helped shape treats serotonin not as a "happiness molecule" but as a stress hormone - one whose elevation in the context of chronic illness reflects and reinforces the same metabolic suppression the protocol is designed to reverse. Understanding this framing is essential to understanding why cyproheptadine holds such a prominent position in the bioenergetic compound stack.

Peat's anti-serotonin argument, consistently developed across his newsletters and writing, rests on serotonin's peripheral physiology rather than its popular-media neuroscience identity. The gut's enterochromaffin cells - which produce approximately 90 percent of total body serotonin - ramp up serotonin synthesis under conditions of reduced oxidative phosphorylation, elevated intestinal bacterial fermentation, and metabolic stress. The peripheral serotonin released into the bloodstream produces a cascade of effects that the bioenergetic framework classifies as metabolic suppressors: vasoconstriction (reducing tissue oxygen delivery), stimulation of cortisol release from adrenal tissue (which in turn suppresses thyroid T3 conversion at the deiodinase level), promotion of platelet aggregation and the inflammatory cascade, and - critically - direct inhibition of mitochondrial Complex I electron transport. This last mechanism is the mechanistic linchpin: serotonin does not merely accompany metabolic suppression, it directly perpetuates it by impairing the very electron transport chain function that would relieve it.

The feedback loop the bioenergetic framework identifies is self-reinforcing: chronic metabolic suppression drives enterochromaffin serotonin overproduction, which drives further mitochondrial Complex I inhibition, which deepens the metabolic suppression, which sustains the serotonin elevation. Breaking this cycle requires a pharmacological intervention at the 5-HT2 receptor level, and the bioenergetic research community Peat helped shape has converged on cyproheptadine as the cleanest available tool for that intervention. The full protocol context - including how cyproheptadine fits alongside T3, pregnenolone, progesterone, and the dietary framework - is developed in the Ray Peat protocol complete 2026 research guide.

What distinguishes cyproheptadine from other anti-serotonin options available to research subjects is the specificity and cleanliness of its mechanism. It does not increase serotonin synthesis (as tryptophan precursor restriction strategies can fluctuate). It does not affect serotonin reuptake (as SSRIs do, producing complex reuptake-dependent receptor regulation effects). It blocks the 5-HT2A and 5-HT2C receptors directly and reversibly - a pharmacological action that maps precisely onto the receptor subtypes the bioenergetic framework identifies as most relevant to peripheral metabolic suppression.

Mechanism: 5-HT2A and H1 Antagonism

Cyproheptadine's receptor-binding profile has been characterized in radioligand displacement studies and in functional receptor assays. The key binding affinities are: high affinity for 5-HT2A (Ki approximately 5 nM in human receptor preparations), high affinity for 5-HT2C (Ki in a similar low-nanomolar range), high affinity for H1 histamine receptors, and moderate affinity for muscarinic M1 and M3 receptors (which underlies the anticholinergic side effects - dry mouth, mild constipation - in the tolerability profile). The 5-HT2B receptor is also bound with moderate affinity, though this subtype receives less attention in the bioenergetic-framework literature because its most documented functions are cardiovascular rather than metabolic.

The 5-HT2A receptor subtype is the most pharmacologically significant target for the bioenergetic framework's anti-serotonin goals. 5-HT2A receptors are expressed on vascular smooth muscle cells (where their activation produces vasoconstriction), on adrenal cortex cells (where their activation amplifies the cortisol response to stress), on platelet membranes (where their activation promotes aggregation), and in the central nervous system on cortical neurons (where their activation is implicated in the anxiety and sleep-disrupting effects of serotonin excess). Blockade of 5-HT2A across these tissue compartments simultaneously addresses the vasoconstriction, the cortisol amplification, and the platelet-aggregation mechanisms that the bioenergetic framework identifies as serotonin's most metabolically suppressive actions.

The 5-HT2C receptor subtype handles a distinct but complementary set of functions. 5-HT2C receptors are expressed in the hypothalamus and brainstem, where their activation promotes satiety (reducing appetite) and contributes to anxiogenic signaling. Cyproheptadine's 5-HT2C antagonism is the mechanistic basis for its well-documented appetite-stimulating effect: by blocking the hypothalamic satiety-promoting 5-HT2C signaling, cyproheptadine effectively removes a brake on appetite regulation. This is not a peripheral effect - it is a central hypothalamic mechanism, which is why cyproheptadine's appetite-stimulating effect is one of the most reproducible pharmacological actions in its clinical profile.

H1 receptor antagonism adds a distinct and complementary layer. Histamine, like serotonin, is a biogenic amine with peripheral vasoactive and inflammatory properties. H1 blockade reduces the histamine-driven component of the inflammatory and vasoconstriction cascade - an additive anti-inflammatory and anti-vasoconstrictive effect alongside the 5-HT2A-mediated actions. Histamine also has a documented interaction with thyroid signaling: H1 receptor activation in thyroid tissue has been shown to modulate thyroid hormone synthesis, and the histamine-serotonin interaction with thyroid-axis regulation is an active area in the receptor pharmacology literature. The dual H1 + 5-HT2 blockade that cyproheptadine produces therefore addresses both the serotonin-driven and the histamine-driven components of the metabolic suppression cascade simultaneously - a pharmacological breadth that no purely anti-serotonin compound can replicate.

Dose Ranges in Research Context

The sedation tolerance timeline is worth elaborating for research context. The initial sedative effect is driven by central H1 receptor blockade - the same mechanism responsible for the well-known sedation profile of first-generation antihistamines as a class. As H1 receptor expression adapts to sustained blockade over 5-10 days, the sedative effect diminishes, while the 5-HT2A and 5-HT2C receptor antagonism - which does not produce sedation directly - continues at the same potency. This differential tolerance development means that a 4 mg dose that produces notable daytime sleepiness in week one typically produces minimal sedation after the first 10 days of consistent use - a feature that distinguishes cyproheptadine from antihistamines that research subjects experience as persistently sedating.

The bioenergetic research community commonly begins with evening dosing only during the initial tolerance-development window, then transitions to morning-plus-evening dosing once the daytime sedation has resolved. Evening dosing in particular is noted in research forums for its sleep-depth benefits (via 5-HT2 antagonism's effect on slow-wave sleep architecture) during the period when the H1-sedation is still prominent - producing a combined sleep-onset facilitation from both the H1 antihistamine mechanism and the sleep-architecture improvement from 5-HT2 blockade.

Appetite, Sleep, and Anxiety Effects

Cyproheptadine's appetite-stimulating effect is one of the best-documented pharmacological actions in its clinical literature - a finding that dates to the earliest controlled trials following its 1961 FDA approval. The mechanism is well-characterized: 5-HT2C receptor blockade in the hypothalamic ventromedial nucleus removes the satiety-promoting serotonin signal that normally acts as a brake on feeding behavior. Clinical trials in underweight adults and children documented consistent weight gain with cyproheptadine administration, with appetite increases typically evident within the first week of use. A 2005 mechanism review in the peer-reviewed literature (PMID 15741327) confirmed that this effect is directly attributable to 5-HT2C antagonism rather than H1 blockade - a finding that helps distinguish the appetite effect from the sedation, which is H1-mediated and tolerance-developing, while appetite stimulation can persist throughout the duration of use.

For bioenergetic-framework research, the appetite-stimulating effect of cyproheptadine has a dual significance. In the immediate sense, it counteracts the appetite suppression that can accompany high-stress states, which is relevant for the chronic-illness research population where appetite dysregulation is common. In the mechanistic sense, it is a biomarker for 5-HT2C receptor engagement: observing increased appetite after initiating cyproheptadine use provides a direct functional readout that the compound is reaching and occupying 5-HT2C receptors in the hypothalamus - confirming CNS penetrance and receptor engagement at a clinically observable level.

The sleep-depth effects of cyproheptadine are mechanistically distinct from its appetite effects and from its sedation. 5-HT2A receptor antagonism has a well-documented effect on sleep architecture: 5-HT2A blockade specifically extends slow-wave sleep (SWS, also called deep sleep or N3 sleep) at the expense of lighter sleep stages. This effect is mechanistically similar to the sleep architecture improvement produced by several atypical antipsychotics that also carry 5-HT2A antagonism - mirtazapine is the canonical example in the clinical literature. The SWS extension is not sedation (it does not reduce time to sleep onset or produce grogginess); it is an improvement in sleep quality defined by increased proportion of the most restorative sleep stage. In the bioenergetic research community, evening cyproheptadine use is specifically discussed as a tool for improving sleep quality in research subjects with serotonin-excess-associated sleep fragmentation - a presentation characterized by frequent waking and reduced slow-wave sleep proportion.

Cyproheptadine's anxiolytic effects follow directly from 5-HT2A receptor antagonism. Activation of 5-HT2A receptors in the prefrontal cortex and amygdala is mechanistically linked to anxiety signaling - the same receptor-level mechanism is exploited by atypical antipsychotics (which share 5-HT2A antagonism with cyproheptadine) for their anti-anxiety effects in generalized anxiety and psychosis-related anxiety. The anxiolytic effect of 5-HT2A blockade in the bioenergetic context is particularly relevant because elevated serotonin - the metabolic-stress marker the bioenergetic framework targets - is itself associated with anxiety amplification through the 5-HT2A pathway. Blocking this receptor interrupts the serotonin-to-anxiety signal at the receptor level rather than upstream (where tryptophan depletion or dietary modification would operate) or downstream (where benzodiazepines act on GABA-A rather than the serotonin signaling cascade).

Pairing with Thyroid Hormone: The Bioenergetic Stack

The canonical bioenergetic pairing is cyproheptadine with slow-release T3 - and the mechanistic logic of this combination is more precise than simple protocol convention. Cyproheptadine and SR-T3 target opposite ends of the same metabolic regulation axis: cyproheptadine suppresses serotonin (the metabolic brake), while SR-T3 elevates metabolic rate (the metabolic accelerator). Together, they address both ends of the regulatory cascade simultaneously in a way that neither compound can achieve alone.

The serotonin-metabolism feedback loop described in the Ray Peat context section makes this complementarity structurally necessary. Serotonin suppresses mitochondrial Complex I, drives cortisol release that impairs T3 conversion at the DIO1 and DIO2 deiodinase level, and promotes the inflammatory cytokines that further suppress deiodinase activity. If SR-T3 is administered without addressing serotonin elevation, the serotonin-driven cortisol and inflammatory load continues to work against the T3's metabolic effects - blunting or delaying the response. Cyproheptadine's 5-HT2A blockade removes this serotonin-driven resistance to T3 signaling, creating a cellular environment that is more receptive to the metabolic-rate elevation that T3 drives. In practical terms, the research community reports that the cyproheptadine + SR-T3 combination produces more consistent and sustained metabolic response than T3 alone - an outcome that the mechanistic complementarity predicts.

The complete bioenergetic stack guide covering this combination is in the sustained-release T3 complete guide, which details the pharmacokinetic rationale for SR-T3 over immediate-release formulations and the cyclic T3 protocol framework that the bioenergetic community favors. The Wilson's SR-T3 Combo Kit is the reference research product for the SR-T3 component of this stack, formulated in hydroxypropyl methylcellulose (HPMC) sustained-release matrix to deliver T3 over a 4-8 hour window rather than as an immediate bolus.

For research subjects investigating the T3 + T2 extension of the bioenergetic protocol, the Wilson's T3+T2 Combo adds the downstream 3,5-diiodothyronine (T2) mitochondrial mechanism to the T3 nuclear receptor action - addressing the deiodinase conversion bottleneck at the T3-to-T2 step that T3-alone protocols leave unaddressed. The interaction between the cyproheptadine anti-serotonin mechanism and the T3+T2 combination is covered in the T3-to-T2 conversion problem and deiodinase dysfunction guide, which details how the same serotonin-driven inflammatory and cortisol signaling that suppresses T4-to-T3 conversion also suppresses the downstream T3-to-T2 conversion step - making anti-serotonin tooling relevant to both ends of the conversion cascade.

The practical sequencing question the bioenergetic research community addresses is whether to begin cyproheptadine before, with, or after initiating SR-T3. The general community observation is that beginning cyproheptadine first (or concurrently with T3) is preferable to adding it after T3 has been running for weeks - because the serotonin-suppression removes a source of deiodinase inhibition that would otherwise limit early T3 response, making the T3 initiation period smoother.

Tolerability and Side-Effect Profile

Cyproheptadine's tolerability profile is well-characterized from its decades of clinical use, and for a CNS-active compound with a multi-receptor mechanism, it is notably clean. The major side effects fall into three categories: sedation, anticholinergic effects, and weight gain.

Sedation is the most prominent side effect during initial use and the one most frequently discussed in research forums as a practical limitation. As detailed in the dose section, this sedation is H1-mediated and tolerance-developing: central H1 receptor blockade produces drowsiness through the same mechanism as diphenhydramine (Benadryl) and other first-generation antihistamines, and receptor adaptation over 5-10 days of consistent use reduces the sedative effect substantially. Research subjects who initiate at 2 mg evening-only, maintaining that regimen for a week before increasing dose or adding morning dosing, typically report the sedation transition as manageable. Initiating at 4 mg twice daily without the evening-first adaptation period is associated with the most sedation complaints in the research community.

Dry mouth is the most common anticholinergic side effect and arises from muscarinic M3 receptor blockade in salivary gland tissue. M3 antagonism reduces salivary gland secretion, producing the xerostomia (dry mouth) that is common across the anticholinergic drug class. This effect does not appear to develop significant tolerance - it persists as a consistent but mild feature of cyproheptadine use for most research subjects. Mild constipation from gastrointestinal M3 antagonism (which reduces gut motility) is also reported but at lower frequency than dry mouth.

Weight gain, as discussed in the mechanism and appetite sections, is a direct and pharmacologically predictable consequence of 5-HT2C receptor blockade. For research subjects using cyproheptadine specifically to restore appetite in an underweight or metabolically suppressed state, this is a desired effect rather than a side effect. For research subjects primarily targeting the anti-serotonin metabolic effects without appetite restoration intent, weight gain monitoring is relevant over extended use. The caloric intake mechanism - rather than a direct metabolic effect on adipose tissue - means that weight management through food quantity awareness is the practical mitigation approach.

A note on paradoxical activation: first-generation antihistamines as a class occasionally produce paradoxical stimulation rather than sedation in pediatric populations - a pharmacological idiosyncrasy that is well-documented for diphenhydramine and has been observed with cyproheptadine in case reports. Cyproheptadine is not generally studied in pediatric research contexts in the bioenergetic framework, and this paradoxical activation pattern is not relevant to the adult research-subject population that the bioenergetic community addresses.

Cyproheptadine vs SSRIs and Atypical Antipsychotics

The bioenergetic research community's choice of cyproheptadine as the canonical anti-serotonin tool becomes clearer in contrast to the other pharmacological classes with serotonin-modulating activity.

SSRIs (selective serotonin reuptake inhibitors) - the most widely prescribed class of serotonin-active compounds in mainstream psychiatry - work by blocking the serotonin transporter (SERT), which reduces serotonin clearance from synaptic clefts and increases postsynaptic receptor exposure to serotonin. This is the precise opposite of what the bioenergetic framework seeks: SSRIs increase serotonin signaling at 5-HT2 and other receptor subtypes (including 5-HT3, which is also implicated in gut inflammatory signaling) by prolonging serotonin's receptor contact time. The popular framing of SSRIs as "increasing serotonin" maps, in bioenergetic framework terms, directly onto increasing the very signal that the framework treats as a metabolic suppressor. Cyproheptadine and SSRIs are pharmacologically opposed in their mechanism of action at the 5-HT2 receptor level - which is also why cyproheptadine is used in serotonin syndrome (serotonin toxicity) as a pharmacological antidote to excess serotonergic stimulation from SSRI overdose or SSRI-MAOI combinations.

Atypical antipsychotics (quetiapine, olanzapine, risperidone, mirtazapine - with mirtazapine classified differently but structurally related) share 5-HT2A and often 5-HT2C antagonism with cyproheptadine, which is why they produce similar sleep-architecture improvement, weight gain, and appetite-stimulating effects. The critical pharmacological distinction is dopamine D2 receptor antagonism: all atypical antipsychotics carry D2 blockade as a defining feature of their mechanism, and the bioenergetic framework does not seek dopamine antagonism. D2 receptor blockade produces tardive dyskinesia risk (with chronic use), prolactin elevation (via tuberoinfundibular dopamine pathway blockade), and the blunted motivation and cognitive effects that the antipsychotic class is associated with. These are not effects the bioenergetic research community targets, and they represent a mechanism-burden that cyproheptadine does not carry.

Cyproheptadine is, in this comparison, the cleanest available research tool for pure anti-serotonin action at the 5-HT2 receptor: it shares the 5-HT2A and 5-HT2C antagonism that makes atypical antipsychotics produce their appetite and sleep effects, adds H1 antihistamine activity that addresses the histamine-serotonin interaction the bioenergetic framework considers relevant, and carries none of the dopamine antagonism that makes atypical antipsychotics pharmacologically inappropriate as bioenergetic-protocol compounds.

What Research Has and Hasn't Established

Established:

5-HT2A and H1 antagonism are well-characterized from radioligand binding studies, functional receptor assays, and the clinical pharmacology literature accumulated across cyproheptadine's 60+ years of use. The appetite-stimulating effect is documented in controlled clinical trials dating to the 1960s and is mechanistically explained by 5-HT2C antagonism in the hypothalamic satiety pathway - a finding replicated in the receptor pharmacology literature and consistent with the appetite-stimulating effects of other 5-HT2C antagonists. Cyproheptadine's use in serotonin syndrome treatment and prophylaxis is well-established in the clinical pharmacology and toxicology literature. The sedation profile and its tolerance development are documented from the first-generation antihistamine class literature. Slow-wave sleep extension via 5-HT2A antagonism is documented by polysomnographic studies of 5-HT2-blocking compounds.

Hypothesis:

The bioenergetic framework's broader anti-serotonin protocol use case - chronic-illness research subjects pairing cyproheptadine with sustained-release T3 as a combined metabolic-rate restoration intervention targeting both ends of the serotonin-metabolism feedback loop - is research-community theory, not RCT-validated. The mechanistic case for the pairing is coherent and draws on peer-reviewed individual mechanisms (5-HT2 antagonism, serotonin's peripheral metabolic effects, T3's deiodinase-mediated metabolism regulation), but the integrated protocol has not been tested in randomized controlled trials. The specific claim that cyproheptadine's anti-serotonin action removes resistance to T3 signaling and improves T3 protocol outcomes is plausible from mechanism but is based on community observation and theoretical extrapolation rather than controlled clinical evidence. The appetite-restoration effect of cyproheptadine in metabolically suppressed research subjects, while mechanistically predicted and anecdotally consistent, has not been specifically studied in the chronic-illness-plus-metabolic-suppression population that the bioenergetic community addresses.

Not endorsed by mainstream endocrinology:

Cyproheptadine's use as a metabolic-protocol component - as part of a combined anti-serotonin and thyroid-optimization stack aimed at restoring oxidative phosphorylation and metabolic rate in chronic-illness research subjects - is outside mainstream clinical guidelines. Mainstream endocrinology does not use serotonin antagonism as a metabolic intervention, does not frame serotonin elevation as a driver of hypothyroidism or metabolic suppression in its clinical guidelines, and does not combine cyproheptadine with thyroid hormone supplementation as a protocol recommendation. The FDA indications for cyproheptadine (allergic conditions, appetite stimulation) do not encompass its bioenergetic-framework use context. Researchers working in the bioenergetic framework should be fully aware that the protocol applications described in this guide represent research-community exploration outside the bounds of approved or guideline-recommended medical practice.

Frequently Asked Questions

What is cyproheptadine used for?

Cyproheptadine is FDA-approved for the treatment of allergic conditions (hay fever, urticaria, allergic conjunctivitis) and as an appetite stimulant in underweight adults and children. Off-label, it is used in clinical settings for serotonin syndrome treatment (where its 5-HT2 antagonism directly counteracts serotonin toxicity), for migraine prophylaxis (via 5-HT2-mediated vascular effect reduction), and in a number of gastrointestinal motility conditions where serotonin receptor modulation is relevant. In the bioenergetic-research community, it is used as the primary anti-serotonin pharmacological tool - a research application that extends its documented 5-HT2A and 5-HT2C antagonism into the metabolic suppression framework that Peat's anti-serotonin argument addresses.

How does cyproheptadine work?

Cyproheptadine works through dual receptor antagonism: it blocks H1 histamine receptors (the classic first-generation antihistamine mechanism) and simultaneously blocks 5-HT2A and 5-HT2C serotonin receptors with high affinity. The H1 blockade produces antihistamine and anti-inflammatory effects and crosses the blood-brain barrier to produce the initial sedation associated with first-generation antihistamines. The 5-HT2A blockade reduces the vasoconstriction, cortisol-amplifying, and mitochondrial Complex I-suppressing effects of peripheral serotonin signaling. The 5-HT2C blockade in the hypothalamus removes the satiety-promoting serotonin signal, stimulating appetite. Moderate muscarinic M1/M3 antagonism adds anticholinergic effects (dry mouth, mild constipation) as a secondary pharmacological action. The combination of these receptor-level effects produces the clinical profile - antihistamine, anti-serotonin, appetite-stimulating, sleep-architecture-improving - that makes cyproheptadine distinctive within the antihistamine class.

What dose of cyproheptadine is used in research?

Research forums discuss dose ranges from 2 mg (sleep-support entry level) through 4 mg (standard anti-serotonin dose, 1-2 times daily) to 8-12 mg in split doses for higher-range research contexts. The typical entry approach discussed in the bioenergetic research community is 2 mg in the evening during the first 5-10 days to allow H1 sedation tolerance to develop, then transitioning to 4 mg with the option to add morning dosing once daytime sedation has resolved. These ranges reflect what is discussed in the community research literature - they are not clinical dosing recommendations, and the appropriate research context for any given subject will depend on factors outside the scope of this guide.

Why does cyproheptadine cause weight gain?

Cyproheptadine causes weight gain primarily through 5-HT2C receptor antagonism in the hypothalamic satiety pathway. Serotonin acting at hypothalamic 5-HT2C receptors promotes satiety and reduces appetite - the basis of several weight-management drugs that are 5-HT2C agonists. Cyproheptadine blocks these receptors, removing the satiety signal and increasing caloric intake over time. The effect is centrally mediated (hypothalamic) rather than peripheral, meaning cyproheptadine does not directly alter adipose tissue metabolism, fat storage enzymes, or metabolic rate. The weight gain is therefore purely appetite-driven: caloric intake increases, and if intake exceeds expenditure, weight increases. This mechanism also explains why the weight-gain effect persists beyond the sedation tolerance window - 5-HT2C receptor adaptation does not follow the same tolerance pattern as H1 receptor adaptation.

How long does cyproheptadine take to work?

The different effects of cyproheptadine operate on different time scales. The initial sedation from H1 blockade appears within 1-2 hours of the first dose and peaks within the first few days of use before tolerance begins to develop. Appetite stimulation, via 5-HT2C antagonism, is typically noticeable within the first week of consistent use. The sleep-depth improvement from 5-HT2A-mediated slow-wave sleep extension is often reported within the first few nights of evening dosing. The broader anti-serotonin metabolic effects - including any observed reduction in vasoconstriction, anxiety, and stress-response reactivity - generally develop over the first 2-4 weeks as consistent receptor blockade is established and the downstream metabolic adaptations to reduced serotonin signaling accumulate.

Can cyproheptadine be combined with T3?

The bioenergetic research community routinely discusses the cyproheptadine + sustained-release T3 combination as the canonical metabolic protocol pairing. The mechanistic rationale is that cyproheptadine's anti-serotonin action removes a source of deiodinase inhibition and cellular resistance to T3 signaling (via serotonin's cortisol-amplifying and inflammatory effects), creating a more receptive cellular environment for the metabolic-rate elevation that T3 drives. The combination is not an approved clinical protocol and its combined use has not been studied in controlled trials. It represents a research-community theoretical and practical development based on extrapolation from the established pharmacologies of each compound individually. Researchers considering this combination should conduct their own review of the individual compound profiles and the relevant research literature.

Is cyproheptadine the same as Periactin?

Yes. Periactin was the original brand name under which cyproheptadine was marketed following its 1961 FDA approval by Merck, Sharp and Dohme. The Periactin brand has been discontinued in many markets, and cyproheptadine is now widely available as a generic under its chemical name. Other historical brand names in international markets include Practin, Viternum, and Apetito. All of these refer to the same active pharmaceutical ingredient: cyproheptadine hydrochloride, C21H21N, with the same molecular structure, receptor profile, and pharmacological action.

Where can I find research-grade cyproheptadine?

Research-grade cyproheptadine for laboratory research use is available directly through this site. The Cyproheptadine 4mg (50 Tablets) is the reference product for bioenergetic-framework research applications, formulated at the 4 mg per tablet dose that corresponds to the standard anti-serotonin research context range. For researchers building the full bioenergetic stack, the Wilson's SR-T3 Combo Kit is the companion SR-T3 product for the canonical cyproheptadine + slow-release T3 pairing. The complete research compound catalog is available at /catalog.

Closing Note

Cyproheptadine's position in the bioenergetic-research protocol rests on a pharmacological profile that is unusually well-matched to the mechanism the bioenergetic framework targets: dual 5-HT2A and H1 antagonism that addresses both serotonin-driven metabolic suppression and the histamine-serotonin interaction with thyroid signaling, without the dopamine antagonism or reuptake-mechanism complexity that makes other serotonin-modulating compounds less suitable as research tools. All compounds on this site are sold strictly for research use. The Cyproheptadine 4mg (50 Tablets) and the Wilson's SR-T3 Combo Kit are available directly - alongside the full catalog of bioenergetic-framework research compounds.